Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q1 2026 · 10-Q
Revenue—
Net Income-$26.19M-$26.19MN/M vs Q1 2025 EPS Diluted-$0.25-$0.25N/M vs Q1 2025 Operating Income-$28,281,000N/M Operating Cash Flow-$31,468,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Free Cash Flowderived-$38,326,000N/M ended Mar 31, 2026 · filed May 11, 2026 · 41 d after period end